Shares dropped 4.3% as investors were disappointed by flat revenue and continued shipment delays in the Middle East, which weighed on growth despite cost-cutting efforts and early traction in medical revenue.

• Total revenue held steady at approximately $2.2 million year-over-year, impacted by $200,000 in delayed Middle East shipments due to regional conflict.
• Gross margin slightly declined to 72.3% from 73.8%, indicating modest margin compression.
• Operating loss improved by 58% to $828,000, driven by a 30% reduction in operating expenses (~$1.3 million savings).
• Medical segment revenue more than doubled to around $108,000, reflecting early-stage adoption of CompuFlo but still a small contribution overall.
• Management reaffirmed 2026 revenue guidance of $9.8 million to $10.2 million, projecting double-digit growth and reduced cash burn despite near-term headwinds.